The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may ...

A recent study marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. As a proof-of-concept, the ...

Researchers just discovered super stem cells capable of resetting themselves back to a stronger, younger version.

In the new book Personhood, historian and law professor Mary Ziegler explores how the push to grant embryos and fetuses full ...

Stem cells are nature’s built-in repair crew, holding the power to regenerate tissues and maintain youthful features. Yet not ...